Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?

Abstract:

:Stevens-Johnson syndrome is a severe and potentially life-threatening cutaneous reaction associated with lamotrigine. The incidence of developing Stevens-Johnson syndrome during lamotrigine therapy is low. On the basis of the glutamate and dopamine neuron dysregulation hypothesis in schizophrenia, we propose new strategies for the treatment of schizophrenic patients using a glutamate system stabilizer lamotrigine as an adjunctive treatment for the poor responders of a dopamine system stabilizer, aripiprazole. The finding of Stevens-Johnson syndrome in two cases out of three treated with lamotrigine plus aripiprazole, however, has a much higher index of suspicion and it is correct to warn of its possible raised risk. As lamotrigine is currently licensed for the prophylactic treatment of bipolar depression, many of these patients have psychotic features where it would be considered reasonable to add an antimanic atypical antipsychotic such as aripriprazole. The two case reports raised the question about the possible increased risk of Stevens-Johnson syndrome with the combination therapy.

authors

Shen YC,Chen SJ,Lin CC,Chen CH

doi

10.1097/01.yic.0000224789.21406.81

subject

Has Abstract

pub_date

2007-07-01 00:00:00

pages

247-8

issue

4

eissn

0268-1315

issn

1473-5857

pii

00004850-200707000-00011

journal_volume

22

pub_type

杂志文章
  • The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder.

    abstract::The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0000000000000175

    authors: Golubchik P,Rapaport M,Weizman A

    更新日期:2017-09-01 00:00:00

  • Carbamazepine in rapid cycling bipolar affective disorder.

    abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198804000-00003

    authors: Joyce PR

    更新日期:1988-04-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00

  • Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

    abstract::Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000097

    authors: Peselow ED,Clevenger S,IsHak WW

    更新日期:2016-07-01 00:00:00

  • Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.

    abstract::The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assess...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000029

    authors: Golubchik P,Sever J,Weizman A

    更新日期:2014-07-01 00:00:00

  • Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis.

    abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199805000-00006

    authors: Gadre DV,Talwar V,Gupta HC,Murthy PS

    更新日期:1998-05-01 00:00:00

  • Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

    abstract::One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Goodman WK,Kozak MJ,Liebowitz M,White KL

    更新日期:1996-03-01 00:00:00

  • The conundrum of depression clinical trials: one size does not fit all.

    abstract::In this paper we review the history of antidepressant (AD) development, since the discovery of imipramine in 1957 to the present day. Through this exploration we will show that the increasing placebo response is likely a red herring and that a higher magnitude of placebo response is not an adequate explanation for AD ...

    journal_title:International clinical psychopharmacology

    pub_type: 历史文章,杂志文章,评审

    doi:10.1097/YIC.0000000000000229

    authors: Khan A,Mar KF,Brown WA

    更新日期:2018-09-01 00:00:00

  • Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions.

    abstract::Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199400910-00005

    authors: Hawley CJ,Roberts AG,Baldwin DS

    更新日期:1994-04-01 00:00:00

  • Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.

    abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Eriksson E

    更新日期:1999-05-01 00:00:00

  • Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

    abstract::The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.yic.0000137184.64610.c8

    authors: Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

    更新日期:2004-09-01 00:00:00

  • Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

    abstract::Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0000000000000016

    authors: Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

    更新日期:2014-03-01 00:00:00

  • Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin.

    abstract::It has been suggested that dopamine/serotonin (5-HT) imbalance, with relative enhancement of serotonergic activity, might be one of the possible pathophysiological mechanisms underlying neuroleptic-induced akathisia. On the basis of preclinical data, which imply that the partial 5-HT1A agonist buspirone possesses anti...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199709000-00003

    authors: Poyurovsky M,Weizman A

    更新日期:1997-09-01 00:00:00

  • A novel approach to rater training and certification in multinational trials.

    abstract::Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280803dad

    authors: Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

    更新日期:2007-07-01 00:00:00

  • Controlled comparison of two different doses of milnacipran in major depressive outpatients.

    abstract::We compared the antidepressant efficacy and patient tolerance of two different doses of milnacipran (75 mg and 150 mg daily) in 66 outpatients with major depression, using the 17-item Hamilton Depression Rating Scale (HDRS). Only new patients who had never experienced frank depressive episodes before, or those who had...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200411000-00005

    authors: Kanemoto K,Matsubara M,Yamashita K,Tarao Y,Inada E,Sekine T

    更新日期:2004-11-01 00:00:00

  • Rationalizing antidepressants for elderly people.

    abstract::A rational approach to the use of antidepressants in the elderly must consider the evidence as to whether such treatment is efficacious (in controlled trials) and effective in clinical practice. Effective treatment of depression depends on its detection, and the subsequent initiation and continuation of adequate treat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199503001-00007

    authors: Katona C

    更新日期:1995-03-01 00:00:00

  • Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial.

    abstract::Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000251

    authors: Segev A,Evans A,Hodsoll J,Whiskey E,Sheriff RS,Shergill S,MacCabe JH

    更新日期:2019-03-01 00:00:00

  • The under-recognized role of dopamine in the treatment of major depressive disorder.

    abstract::Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patien...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282f2b3cb

    authors: Montgomery SA

    更新日期:2008-03-01 00:00:00

  • Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

    abstract::Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0b013e32830c2042

    authors: Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

    更新日期:2008-11-01 00:00:00

  • Somnambulistic-like behaviour in patients attending a lithium clinic.

    abstract::The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Landry P,Warnes H,Nielsen T,Montplaisir J

    更新日期:1999-05-01 00:00:00

  • Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems.

    abstract::An assessment of the efficacy of treatments in panic disorder and agoraphobia (PDA) is complicated by methodological problems resulting from the complexity of these disorders. In this paper, commonly used anxiety scales are discussed with regard to their relevance in the assessment of PDA. Although there are already m...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199506000-00004

    authors: Bandelow B,Hajak G,Holzrichter S,Kunert HJ,Rüther E

    更新日期:1995-06-01 00:00:00

  • The relationship between social phobia and avoidant personality disorder: workshop report 3.

    abstract::Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

    journal_title:International clinical psychopharmacology

    pub_type:

    doi:

    authors: Dahl AA

    更新日期:1996-06-01 00:00:00

  • Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.

    abstract::We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/YIC.0000000000000177

    authors: Pae CU,Wang SM,Han C,Bahk WM,Lee SJ,Patkar AA,Masand PS,Serretti A,Emsley R

    更新日期:2017-09-01 00:00:00

  • Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder.

    abstract::Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD. Analogous to depression, however, some PTSD patients may not have a satisfactory response to these agents. This case report de...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199809000-00008

    authors: Hamner MB,Frueh BC

    更新日期:1998-09-01 00:00:00

  • Treatment of generalized anxiety disorder with citalopram.

    abstract::Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200205000-00002

    authors: Varia I,Rauscher F

    更新日期:2002-05-01 00:00:00

  • Refining treatment approaches in obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199612005-00003

    authors: Fineberg N

    更新日期:1996-12-01 00:00:00

  • Comparison of the association of risperidone and quetiapine with deteriorating performance in walking and dressing in subjects with Parkinson's disease: a retrospective cohort study using administrative claims data.

    abstract::This retrospective cohort study was performed to investigate the association between risperidone and deteriorating performance in walking and dressing in subjects with Parkinson's disease using the Japanese Diagnosis Procedure Combination data. These data include inpatient claims including information from the time of...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000274

    authors: Iketani R,Imai S,Horiguchi H,Furushima D,Fushimi K,Yamada H

    更新日期:2019-09-01 00:00:00

  • Abnormal correlation between serum leptin levels and body mass index may predict metabolic dysfunction irrespective of the psychopharmacological treatment.

    abstract::In an earlier study, we found a similar frequency of individuals with an abnormal correlation between serum leptin levels and body mass index (BMI) (outliers above or below the 95% confidence interval in the regression line) during treatment with antipsychotic drugs (n=301), other psychotropic drugs (n=65), and drug-f...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e328342ce47

    authors: Marquina D,Peña R,Fernández E,Baptista T

    更新日期:2011-05-01 00:00:00

  • The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.

    abstract::Depression compromises affected individuals' functional well-being and impairs their level of social and workplace performance. Improved social functioning in depressed patients may improve their work productivity. This study evaluated the differential effects of two antidepressants on social functioning outcomes for ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015050-00005

    authors: Venditti LN,Arcelus A,Birnbaum H,Greenberg P,Barr CE,Rowland C,Williamson T

    更新日期:2000-09-01 00:00:00

  • Effects of risperidone on affective symptoms in patients with schizophrenia.

    abstract::The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-200015060-00005

    authors: Peuskens J,Van Baelen B,De Smedt C,Lemmens P

    更新日期:2000-11-01 00:00:00